Giacomo Pirovano1, Sheryl Roberts1, Christian Brand1, Patrick L Donabedian1, Christian Mason1, Paula Demétrio de Souza1, Geoff S Higgins2, Thomas Reiner3,4. 1. Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 2. CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK. 3. Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. reinert@mskcc.org. 4. Department of Radiology, Weill Cornell Medical College, New York, NY, USA. reinert@mskcc.org.
Abstract
PURPOSE: Lymphokine-activated killer T cell-originated protein kinase (TOPK) is a fairly new cancer biomarker with great potential for clinical applications. The labeling of a TOPK inhibitor with F-18 can be exploited for positron emission tomography (PET) imaging allowing more accurate patient identification, stratification, and disease monitoring. PROCEDURES: [18F]FE-OTS964 was produced starting from OTS964, a preclinical drug which specifically binds to TOPK, and using a two-step procedure with [18F]fluoroethyl p-toluenesulfonate as a prosthetic group. Tumors were generated in NSG mice by subcutaneous injection of U87 glioblastoma cells. Animals were injected with [18F]FE-OTS964 and PET imaging and ex vivo biodistribution analysis was carried out. RESULTS: [18F]FE-OTS964 was successfully synthesized and validated in vivo as a PET imaging agent. The labeling reaction led to 15.1 ± 7.5 % radiochemical yield, 99 % radiochemical purity, and high specific activity. Chemical identity of the radiotracer was confirmed by co-elution on an analytical HPLC with a cold-labeled standard. In vivo PET imaging and biodistribution analysis showed tumor uptake of 3.06 ± 0.30 %ID/cc, which was reduced in animals co-injected with excess blocking dose of OTS541 to 1.40 ± 0.42 %ID/cc. CONCLUSIONS: [18F]FE-OTS964 is the first TOPK inhibitor for imaging purposes and may prove useful in the continued investigation of the pharmacology of TOPK inhibitors and the biology of TOPK in cancer patients.
PURPOSE:Lymphokine-activated killer T cell-originated protein kinase (TOPK) is a fairly new cancer biomarker with great potential for clinical applications. The labeling of a TOPK inhibitor with F-18 can be exploited for positron emission tomography (PET) imaging allowing more accurate patient identification, stratification, and disease monitoring. PROCEDURES: [18F]FE-OTS964 was produced starting from OTS964, a preclinical drug which specifically binds to TOPK, and using a two-step procedure with [18F]fluoroethyl p-toluenesulfonate as a prosthetic group. Tumors were generated in NSG mice by subcutaneous injection of U87glioblastoma cells. Animals were injected with [18F]FE-OTS964 and PET imaging and ex vivo biodistribution analysis was carried out. RESULTS: [18F]FE-OTS964 was successfully synthesized and validated in vivo as a PET imaging agent. The labeling reaction led to 15.1 ± 7.5 % radiochemical yield, 99 % radiochemical purity, and high specific activity. Chemical identity of the radiotracer was confirmed by co-elution on an analytical HPLC with a cold-labeled standard. In vivo PET imaging and biodistribution analysis showed tumor uptake of 3.06 ± 0.30 %ID/cc, which was reduced in animals co-injected with excess blocking dose of OTS541 to 1.40 ± 0.42 %ID/cc. CONCLUSIONS: [18F]FE-OTS964 is the first TOPK inhibitor for imaging purposes and may prove useful in the continued investigation of the pharmacology of TOPK inhibitors and the biology of TOPK in cancerpatients.
Authors: Fang Hu; Ronald B Gartenhaus; Xianfeng F Zhao; Hong-Bin Fang; Samuel Minkove; Daniella E Poss; Aaron P Rapoport Journal: Leuk Res Date: 2012-12-10 Impact factor: 3.156
Authors: I Zlobec; F Molinari; M Kovac; M P Bihl; H J Altermatt; J Diebold; H Frick; M Germer; M Horcic; M Montani; G Singer; H Yurtsever; A Zettl; L Terracciano; L Mazzucchelli; P Saletti; M Frattini; K Heinimann; A Lugli Journal: Br J Cancer Date: 2009-11-24 Impact factor: 7.640
Authors: Thomas C Wilson; Stephen A Jannetti; Navjot Guru; Nagavarakishore Pillarsetty; Thomas Reiner; Giacomo Pirovano Journal: Int J Radiat Biol Date: 2020-07-02 Impact factor: 2.694
Authors: Patricia M R Pereira; Sheryl Roberts; Flávio Figueira; João P C Tomé; Thomas Reiner; Jason S Lewis Journal: J Nucl Med Date: 2020-01-31 Impact factor: 10.057